

15 Dec 2020 | News

QUOTED. 15 December 2020. Jessica Schubel.

by

Experts speculate a Good Guidance Practices regulation from the US HHS will delight the medtech industry but see FDA pushback. Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities, expressed concerns.

"I think everyone is a loser in terms of having this reg finalized, because it's implementing a process that is totally unnecessary." – Jessica Schubel, senior policy analyst, Center on Budget and Policy Priorities

• Find out more: <u>Lauded By Industry, Loathed By FDA? New HHS</u> 'Good Guidance' Rule Likely <u>Ruffling Feathers</u>

<u>Click here</u> for a free trial of Medtech Insight